Researcher
Oliver Bechter
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Member
From7 May 2012 → Today
Projects
1 - 5 of 5
- Dissecting the heterotypic cell communication networks at the perivascular niche to detect andintercept the early metastatic processFrom1 Jan 2023 → TodayFunding: BOF - iBOF
- Multiplexed immunohistochemistry and digital pathology as the foundation for next-generation pathology in melanoma researchFrom1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Next-generation pathology by MILAN: multiplex immunohistochemistry and advanced trainable image analysisFrom1 Jan 2020 → 31 Dec 2021Funding: IOF - technology validation in lab
- Preventing therapy-induced cancer stemnessFrom1 Oct 2019 → TodayFunding: IOF - technology concept exploration, BOF - projects
- Treating melanoma as an infectious diseaseFrom1 Sep 2018 → 31 Aug 2022Funding: Foundations, funds and other with scientific goal
Publications
41 - 50 of 81
- 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO plus IPI) or NIVO alone(2020)
Authors: C Robert, GV Long, J Larkin, JD Wolchok, JC Hassel, D Schadendorf, FS Hodi, C Lebbe, J-J Grob, K Grossmann, et al.
Pages: S734 - S735 - Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial(2020)
Authors: Oliver Bechter
Pages: 94 - 103 - Gastric Tumoral Melanosis: a Rare Manifestation of Successfully Treated Malignant Melanoma(2020)
Authors: Xavier Sagaert, Oliver Bechter
Pages: A37 - A38 - Isolated limb perfusion in the treatment of in-transit melanoma metastases: are these predictive factors for the outcome?(2020)
Authors: Veerle Boecxstaens, Maria Garmyn, Joost van den Oord, Oliver Bechter
Pages: 2 - 8 - Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors(2020)
Authors: Oliver Bechter, Patrick Schöffski
- Myositis as a neuromuscular complication of immune checkpoint inhibitors(2020)
Authors: Christophe Depuydt, Oliver Bechter, Philip Van Damme, Dietmar Thal, Kristl Claeys
Pages: 355 - 364 - High Resolution Multiplexing of Melanoma Microenvironment in Responders/Non-Responders to Checkpoint Therapy(2020)
Authors: Francesca Bosisio, Asier Antoranz, Yannick Van Herck, Maddalena Bolognesi, Seohdna Lynch, Arman Rahman, William Gallagher, Giorgio Cattoretti, Joost van den Oord, Oliver Bechter
Pages: 457 - 458 - Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing(2020)
Authors: Francesca Bosisio, Yannick Van Herck, Lukas Marcelis, Jasper Wouters, Veerle Boecxstaens, Oliver Bechter, Joost van den Oord
- Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis(2020)
Authors: Patrick Schöffski, Daphne Hompes, Paul De Leyn, Willy Coosemans, Dirk Van Raemdonck, Esther Hauben, Raf Sciot, Paul Clement, Oliver Bechter, Benoit Beuselinck, et al.
Pages: 1 - 9 - Clinical presentation, treatment modalities and outcome in patients with adrenocortical carcinoma: A single center experience(2020)
Authors: Annouschka Laenen, Oliver Bechter
Pages: 209 - 213